Click here to read the articles and download the PDF

Pharmaceutical Commerce - December 2024

Because of the potential for product shortages at pharmacies, the FDA has not only given industry more time for compliance—but time to catch up on boosting the supply chain’s interoperable efforts.

Did Industry Fumble the DSCSA Deadline?

A crash course on the bubble itself, including therapeutic areas most affected.

Going Inside the Gross-to-Net Bubble and Its Nuances

Addressing the bottlenecks in cell and gene therapy manufacturing through a well-designed artificial intelligence approach is essential to avoiding data siloes.

Why AI Advances in CGT Require Getting Data Right

Articles

These medications are used to treat a multitude of conditions including type 2 diabetes, cancer and asthma.

Headlined by Ozempic, Medicare Reveals Second Round of Drugs Selected for Price Negotiations

Videos

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Donald Prentiss, founder and CEO, Qualthera, describes compounding pharmacies’ efforts in tackling the tirzepatide shortage, and dispels the notion that commercialized and compounded drugs are competing with one another.

Clearing Up the Competition Myth

The latest news for pharma industry insiders.

Pharma Pulse 1/17/25: Telehealth, the Fully Hybridized Version, Why Pharma’s DTP Approach Should Be Applauded & more

CVS Caremark, Express Scripts, OptumRx made more than $7.3 billion in revenue, with markups as high as thousands of percent. 

FTC Report Finds Big Three PBM Mark Ups for Specialty Generics Generated Billions

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Donald Prentiss, founder and CEO, Qualthera, comments on the role that compounding pharmacies play in the pharmaceutical supply chain from a macro perspective.

The Role of Compounding Pharmacies in Meeting Patient Needs

Pharma Pulse 1/16/25: The Recipe for Relief, AI Soups up Payer Operations & more

Cryoport's business unit, Cryogene, will be tasked with helping to foster the growth of Moffitt’s cell and gene therapy efforts.

Moffitt Cancer Center, Cryoport Strike Biorepository Agreement

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Mark Jara, founder and CTO, RxS, comments on how personalization could play a role in the future development of eSampling platforms.

The Future of eSampling Portals

Pharma Pulse 1/15/25: PBMs Mark Up Specialty Generic Drugs, Flurry of Acquisitions/Licensing Deals Amid JPM25 & more

The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.

Featured Content

Pharmaceutical Commerce - December 2024

Did Industry Fumble the DSCSA Deadline?

Going Inside the Gross-to-Net Bubble and Its Nuances

Why AI Advances in CGT Require Getting Data Right